Details for New Drug Application (NDA): 204950
✉ Email this page to a colleague
NDA 204950 describes GANCICLOVIR SODIUM, which is a drug marketed by Am Regent, Custopharm Inc, Endo Operations, Fresenius Kabi Usa, Hikma, Pharmascience Inc, Slate Run Pharma, and Steriscience Speclts, and is included in eight NDAs. It is available from six suppliers. Additional details are available on the GANCICLOVIR SODIUM profile page.
The generic ingredient in GANCICLOVIR SODIUM is ganciclovir sodium. There are twenty-seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ganciclovir sodium profile page.
The generic ingredient in GANCICLOVIR SODIUM is ganciclovir sodium. There are twenty-seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ganciclovir sodium profile page.
Summary for 204950
| Tradename: | GANCICLOVIR SODIUM |
| Applicant: | Endo Operations |
| Ingredient: | ganciclovir sodium |
| Patents: | 0 |
Pharmacology for NDA: 204950
| Mechanism of Action | DNA Polymerase Inhibitors |
Suppliers and Packaging for NDA: 204950
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| GANCICLOVIR SODIUM | ganciclovir sodium | INJECTABLE;INJECTION | 204950 | ANDA | Endo USA, Inc. | 42023-173 | 42023-173-25 | 25 VIAL, SINGLE-DOSE in 1 CARTON (42023-173-25) / 10 mL in 1 VIAL, SINGLE-DOSE (42023-173-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Dec 6, 2016 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
